Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2025)
Candel Therapeutics recorded quarterly Depreciation & Amortization (CF) of $100000.0 in Q4 2025, down 50.0% quarter-over-quarter from $200000.0 in Q3 2025, and down 66.67% year-over-year from $300000.0 in Q4 2024.
Candel Therapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $100000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 66.67% year-over-year to $100000.0; the TTM figure through Dec 2025 stood at $745000.0 (down 25.5% YoY), while the FY2025 annual figure was $800000.0, down 20.0% from the prior year.
- Depreciation & Amortization (CF) came in at $100000.0 for Q4 2025 at Candel Therapeutics, down from $200000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $300000.0 in Q4 2023 to a low of $7000.0 in Q2 2021.
- A 5-year average of $183650.0 and a median of $200000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 2866.67% in 2021 and plunged 66.67% in 2025, its largest moves.
- Candel Therapeutics' Depreciation & Amortization (CF) stood at $178000.0 in 2021, then changed by 0.0% to $178000.0 in 2022, then soared by 68.54% to $300000.0 in 2023, then changed by 0.0% to $300000.0 in 2024, then sank by 66.67% to $100000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $100000.0, $200000.0, and $200000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 245,000.00 |
| Mar 31, 2025 | 245,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 236,000.00 |
| Jun 30, 2023 | 236,000.00 |
| Mar 31, 2023 | 230,000.00 |
| Mar 31, 2023 | 230,000.00 |
| Dec 31, 2022 | 178,000.00 |
| Dec 31, 2022 | 178,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 187,000.00 |
| Jun 30, 2022 | 187,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Dec 31, 2021 | 178,000.00 |
| Dec 31, 2021 | 178,000.00 |
| Sep 30, 2021 | 21,000.00 |
| Sep 30, 2021 | 21,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2020 | 45,000.00 |
| Sep 30, 2020 | 45,000.00 |